The guideline of the Korean College of Helicobacter and Upper Gastrointestinal Research group for Helicobacter pylori infection was first produced in 1998, when definite indication for H. pylori eradication is early gastric cancer in addition to the previous indications of peptic ulcer (PUD) including scar lesion and marginal zone B cell lymphoma (MALT type). Though treatment is recommended for the relatives of a patient with gastric cancer, unexplained iron deficiency anemia, and chronic idiopathic thrombocytopenic purpura, a consensus treatment guideline is the treatment of PUD, MALToma, and gastric cancer in Korea. One- or 2-week treatment with proton pump inhibitor (PPI)-based triple therapy consisting of one PPI and 2 antibiotics, clarithromycin and amoxicillin, is recommended as the first-line treatment regimen. In the case of treatment failure, one or 2 weeks of quadruple therapy (PPI + metronidazole + tetracycline + bismuth) is recommended, whose eradication regimen was not different between Korea and Japan. Though the treatment regimen was similar between two nations, the Japanese government declared the inclusion of H. pylori eradication in patients with H. pylori-associated chronic gastritis, reaching the conclusion that the treatment guideline became quite different between Korea and Japan from February 21, 2013. The prime rationale of the Japanese extended treatment guideline for H. pylori infection was based on the drastic intention to prevent gastric cancer as well as the improvement of chronic gastritis-associated functional dyspepsia based on their findings that H. pylori eradication might decrease gastric cancer incidence as well as mortality. In this review, the discrepancy between the Korean and Japanese treatment guidelines will be explained; why and how?

1.
Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:177-241.
2.
Asaka M: Helicobacter pylori infection and gastric cancer. Intern Med 2002;41:1-6.
3.
Asaka M, Kato M, Graham D: Strategy for eliminating gastric cancer in Japan. Helicobacter 2010;15:486-490.
4.
Asaka M: A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-1276.
5.
Ferlay J, Shin HR, Bray F, et al: Estimation of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 2010;127:2893-2917.
6.
Malfertheiner P, Sipponen P, Naumann M, et al: Helicobacter pylori eradication has potential to prevent gastric cancer: a state-of-the art critique. Am J Gastroenterol 2005;100:2100-2115.
7.
Wu CY, Kuo KN, Wu MS, et al: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009;137:1641-1648.
8.
Fukase K, Kato M, Kikuchi S, et al: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial. Lancet 2008;372:392-397.
9.
Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
10.
Asaka M, Kato M, Takahashi S, et al: Guideline for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
11.
Lee SY: Future candidates for indication of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol 2012;27:200-211.
12.
Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS; Korean College of Helicobacter and Upper Gastrointestinal Research; Korean Association of Gastroenterology: Diagnosis and Treatment guideline for Helicobacter pylori infection in Korea (in Korean). Korean J Gastroenterol 2009;54:269-278.
13.
Jee SR, Jung HK, Min BK, et al: Guidelines for the treatment of functional dyspepsia (in Korean). Korean J Gastroenterol 2011;57:67-81.
14.
Warren JR, Marshall BJ: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.
15.
Hahm KB, Lee KM, Kim YB, et al: Conditional loss of TGF-beta signaling leads to increased susceptibility to gastrointestinal carcinogenesis in mice. Aliment Pharmacol Ther 2002;16:115-127.
16.
Han SU, Kim YB, Joo HJ, Hahm KB, Lee WH, Cho YK, Kim DY, Kim MW: Helicobacter pylori infection promotes gastric carcinogenesis in a mice model. J Gastroenterol Hepatol 2002;17:253-261.
17.
Kim YJ, Chung JW, Lee SJ, Choi KS, Kim JH, Hahm KB: Progression from chronic atrophic gastritis to gastric cancer: tangle, toggle, tackle with Korean red ginseng. J Clin Biochem Nutr 2010;46:195-204.
18.
Chung JW, Hahm KB: Rejuvenation of atrophic gastritis in the elderly. J Gastroenterol Hepatol 2010;25:434-435.
19.
Lee JS, Paek NS, Kwon OS, Hahm KB: Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism. J Gastroenterol Hepatol 2010;25:194-202.
20.
Won I, Kim YJ, Kim SJ, Kim EH, Hahm KB: Nutrigenomic approach to tackle the unpleasant journey to Helicobacter pylori-associated gastric carcinogenesis. J Dig Dis 2011;12:157-164.
21.
Lee SY, Shin YW, Hahm KB: Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis 2008;9:129-139.
22.
Park S, Yeo M, Jin JH, Lee KM, Jung JY, Choue R, Cho SW, Hahm KB: Rescue of Helicobacter pylori-induced cytotoxicity by red ginseng. Dig Dis Sci 2005;50:1218-1227.
23.
Chun KS, Kim EH, Lee S, Hahm KB: Chemoprevention of gastrointestinal cancer: the reality and the dream. Gut Liver 2013;7:137-149.
24.
Siegel R, Naishadham D, Jemal A: Cancer statistics 2013. CA Cancer J Clin 2013;63:11-30.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.